The findings from the CANTATA study in renal cell carcinoma, where glutaminase inhibition was ineffective in an unselected cohort despite a robust mechanistic rationale [71], underscores that success in OS will depend on integrating precise molecular stratification with judicious therapeutic combinations to avert metabolic compensation. The gene discussed is GLS; the disease is renal cell carcinoma.